{"groups":[{"description":"PREPARATIVE REGIMEN: Participants receive melphalan IV over 30-60 minutes on day -2.\n\nTRANSPLANT: Participants in both groups undergo donor stem cell transplantation IV on day 0 over 30-60 minutes.\n\nPOST-TRANSPLANT: Participants in both groups receive filgrastim-sndz SC QD starting on day 5 and continuing in the absence of disease progression, unacceptable toxicity, or until evidence of an ANC of 0.5 x 10\\^9/L.\n\nAutologous Hematopoietic Stem Cell Transplantation: Undergo HSCT\n\nFilgrastim-sndz: Given SC\n\nMelphalan Hydrochloride: Given IV","id":"FG000","title":"Group1_Dose 1 200mgm2"},{"description":"PREPARATIVE REGIMEN: Participants receive melphalan IV over 30-60 minutes on day -2.\n\nTRANSPLANT: Participants in both groups undergo donor stem cell transplantation IV on day 0 over 30-60 minutes.\n\nPOST-TRANSPLANT: Participants in both groups receive filgrastim-sndz SC QD starting on day 5 and continuing in the absence of disease progression, unacceptable toxicity, or until evidence of an ANC of 0.5 x 10\\^9/L.\n\nAutologous Hematopoietic Stem Cell Transplantation: Undergo HSCT\n\nFilgrastim-sndz: Given SC\n\nMelphalan Hydrochloride: Given IV","id":"FG001","title":"Group 1_Dose 2 225mgm2"},{"description":"PREPARATIVE REGIMEN: Participants receive melphalan IV over 8-9 hours on day -2.\n\nTRANSPLANT: Participants in both groups undergo donor stem cell transplantation IV on day 0 over 30-60 minutes.\n\nPOST-TRANSPLANT: Participants in both groups receive filgrastim-sndz SC QD starting on day 5 and continuing in the absence of disease progression, unacceptable toxicity, or until evidence of an ANC of 0.5 x 10\\^9/L.\n\nAutologous Hematopoietic Stem Cell Transplantation: Undergo HSCT\n\nFilgrastim-sndz: Given SC\n\nMelphalan Hydrochloride: Given IV","id":"FG002","title":"Group 2_Dose 1 200mgm2"},{"description":"PREPARATIVE REGIMEN: Participants receive melphalan IV over 8-9 hours on day -2.\n\nTRANSPLANT: Participants in both groups undergo donor stem cell transplantation IV on day 0 over 30-60 minutes.\n\nPOST-TRANSPLANT: Participants in both groups receive filgrastim-sndz SC QD starting on day 5 and continuing in the absence of disease progression, unacceptable toxicity, or until evidence of an ANC of 0.5 x 10\\^9/L.\n\nAutologous Hematopoietic Stem Cell Transplantation: Undergo HSCT\n\nFilgrastim-sndz: Given SC\n\nMelphalan Hydrochloride: Given IV","id":"FG003","title":"Group 2_Dose 225mgm2"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}],"type":"Inadequate supply on study drug"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"}],"type":"Disease Progression"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"27"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"27"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"27"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"27"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"All participants were registered in MD Anderson Cancer Center."}